Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1148/radiol.221177 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers.
BMC Cancer
January 2025
Department of Clinical Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Background: We developed a prognostic model to evaluate the overall survival (OS) and progression-free survival (PFS) of patients with unresectable hepatocellular carcinoma (u-HCC) treated with Hepatic arterial infusion chemotherapy of infusion oxaliplatin, fluorouracil and leucovorin (FOLFOX-HAIC).
Methods: This model was based on a retrospective study of u-HCC patients treated with the FOLFOX-HAIC (oxaliplatin 130 mg/m, leucovorin 400 mg/m, fluorouracil bolus 400 mg/m on day 1, and fluorouracil infusion 2,400 mg/m for 23-46 h, once every 3-4 weeks). We divided the patients into a training cohort and a validation cohort, used LASSO regression construct prognostic models, predict patient's OS and PFS based on nomograms of models.
Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors.
BMC Gastroenterol
January 2025
Department of Interventional Radiology, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin, Heilongjiang Province, 150081, China.
Objective: To develop and validate a computed tomography (CT)-based deep learning radiomics model to predict treatment response and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (uHCC) treated with transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors and tyrosine kinase inhibitors (TKIs).
Methods: This retrospective study included 172 patients with uHCC who underwent combination therapy of TACE-HAIC with TKIs and PD-1 inhibitors. Among them, 122 were from the Interventional Department of the Harbin Medical University Cancer Hospital, with 92 randomly assigned to the training cohort and 30 cases randomly assigned to the testing cohort.
Prognostic and diagnostic value of [F]FDG, C-acetate, and [Ga]Ga-FAPI-04 PET/CT for hepatocellular carcinoma.
Eur Radiol
January 2025
Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Objectives: To assess the prognostic value of Fluorine 18-labeled fluorodeoxyglucose [F]FDG, gallium 68-labeled fibroblast-activation protein inhibitor-04 [Ga]Ga-FAPI-04, C-acetate in hepatocellular carcinoma (HCC) and evaluate the potential usefulness and advantages of different combinations for accurate diagnosis.
Materials And Methods: Thirty-six patients with suspected hepatic masses were prospectively enrolled from May 2021 to September 2022 and underwent [F]FDG, [Ga]Ga-FAPI-04, and C-acetate PET/CT scans before surgery. PET/CT results and histopathologic examinations were independently interpreted by two radiologists and pathologists, respectively.
Genetic risk amplifies lifestyle effects on hepatic steatosis and its progression: Insights from a population-based cohort.
Dig Liver Dis
January 2025
Department of Epidemiology, School of Public Health, Fudan University, Shanghai, PR China; Key Laboratory of Public Health Safety (Fudan University), Ministry of Education, PR China; Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health, Fudan University, Shanghai, 200032, PR China; Yiwu Research Institute, Fudan University, Yiwu, PR China. Electronic address:
Background: Steatotic liver disease (SLD) is influenced by both genetics and lifestyle factors, with lifestyle effects varying by genetic susceptibility. We aimed to evaluate gene-lifestyle interactions on SLD risk.
Methods: We included 28,215 UK Biobank participants with available data.
Evaluation of Liver Volume Estimation Methods in Living Donor Liver Transplant: CT Volumetry vs MeVis, With Comparison of Open and Laparoscopic Surgery.
Transplant Proc
January 2025
Department of Hepatopancreatobiliary & Transplant Surgery, Singapore General Hospital, Singapore; SingHealth Duke-NUS Transplant Centre, Singapore; Duke-NUS Medical School, Singapore.
Background: Accurately assessing graft volume is crucial for donor and recipient safety in living donor liver transplantation. This can be performed using manual computed tomography volumetry (CTvol) or semiautomated methods (MeVis). We aimed to compare CTvol and MeVis in estimating the actual graft weight during LDLT, and analyse any differences in weight between laparoscopic and open donor hepatectomy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!